REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1606174
This article is part of the Research TopicMechanisms of Traumatic Brain Injury and its PharmacotherapyView all 6 articles
Brain Injury Biomarkers as Targets for Drugs Development and Personalized Treatment for Traumatic Brain Injury Patients
Provisionally accepted
- 1Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States
- 2Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Eastern Province, Saudi Arabia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Drug treatment protocols for traumatic brain injury (TBI) that result in long-term, positive outcomes have yet to be determined for various reasons, including diversity of injury and difficulty in measuring outcomes. Brain injury biomarkers are increasingly being used for drug development and treatment research in patients with TBI traumatic brain injury (TBI)to supplement pharmacokinetic studies, provide evidence of drug mechanism of action, detect early and long-term clinical outcomes, and homogenize study populations. Utilizing brain injury biomarkers to determine injury mechanism and severity of injury for inclusion in preclinical and clinical trials allows for less heterogeneity in study populations. Biomarkers can also provide evidence of drug engagement with its target and be used to measure treatment effect. Therefore, correlation of the biomarkers with clinical outcomes has the potential to improve the efficiency and success of drug development and more personalized treatment strategies for TBI.The use of biomarkers to influence TBI drug development and treatment trials has the potential to lead to more innovative research and personalized patient care. Future TBI clinical trials that utilize these innovative biomarkers study designs and demonstrate strong correlations between biomarkers and clinical outcomes could permit shorter, less expensive, and more successful clinical trials.
Keywords: biomarkers, Traumatic Brain Injury, Drug Development, Drug Discovery, Pharmacology
Received: 04 Apr 2025; Accepted: 09 May 2025.
Copyright: © 2025 Sandler, Almohaish and Brophy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sulaiman Almohaish, Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Eastern Province, Saudi Arabia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.